Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MopA, more commonly known as Chaperonin GroEL, is a critical molecular chaperone found in most bacteria, including pathogens like Escherichia coli and Salmonella. It belongs to the Hsp60 family and works in conjunction with its co-chaperonin GroES (MopB) to facilitate the proper folding of nascent polypeptides and the refolding of denatured proteins, particularly under stress conditions such as heat shock. GroEL is essential for bacterial viability and has been implicated in antibiotic resistance, such as ceftriaxone resistance in Salmonella. Due to its fundamental role in bacterial proteostasis and virulence, GroEL is a promising target for the development of novel antimicrobial agents. Additionally, its human homolog, Hsp60, is often overexpressed in various cancers and is being explored as a target for anticancer therapies.
Inhibition of ATPase activity, disruption of the GroEL-GroES interaction, or blocking the substrate-binding site to prevent proper protein folding.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chaperonin GroEL (GroEL).